Sign in

    Robert A. Bradway

    Chairman, CEO, and President at Amgen Inc
    Board
    Since 2012
    Age
    62 years
    Education
    Holds a bachelor's degree in Biology from Amherst College and a master's degree in Business Administration from Harvard Business School.
    Tenure
    Joined AMGN in 2006 as Vice President, Operations Strategy, then served as Executive Vice President and CFO (2007-2010), President and Chief Operating Officer (2010-2012), and has been CEO since 2012 and Chairman since 2013.

    Also at Amgen Inc

    DMR
    David M. Reese
    EVP and Chief Technology Officer
    DM
    Derek Miller
    SVP, Human Resources
    ES
    Esteban Santos
    EVP, Operations

    About

    Robert A. Bradway is a seasoned executive with a strong foundation in both science and finance. Prior to his tenure at AMGN, he honed his expertise in the financial industry, notably serving as a Managing Director at Morgan Stanley in London from 2001, which laid the groundwork for his strategic and operational insights.

    During his time at AMGN, he has consistently driven strategic growth and operational excellence through successive leadership roles. His transition from Vice President, Operations Strategy to key executive positions such as CFO, COO, President, and ultimately CEO underscores a career marked by progressive responsibility and impactful decision-making.

    Beyond his direct contributions at AMGN, his involvement as a board member for prestigious companies—such as The Boeing Company—and his participation in academic and governance bodies highlight a broader commitment to corporate leadership and public policy. This multifaceted experience not only strengthens his executive profile but also reinforces his reputation as a leader who bridges the worlds of biotechnology, finance, and governance.

    $AMGN Performance Under Robert A. Bradway

    Past Roles

    OrganizationRoleDate RangeDetails
    AmgenPresident and Chief Operating Officer2010–2012 Held prior to becoming Chairman, CEO, and President
    AmgenExecutive Vice President and Chief Financial Officer2007–2010 Served as CFO before further promotion
    AmgenVice President, Operations Strategy2006 Early leadership role at Amgen
    Morgan Stanley (London)Managing DirectorStarting in 2001 Oversaw the banking department and corporate finance activities in Europe before joining Amgen

    External Roles

    OrganizationRoleDate RangeDetails
    The Boeing CompanyDirectorSince 2016 Chair of the Finance Committee and member of the Governance and Public Policy Committee
    University of Southern California (USC)TrusteeSince 2014 Serves on the board of trustees

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,786,977 Bi-weeklyFixed base salary earned each bi-weekly pay period before pre-tax contributions
    All Other Compensation$680,456 AnnuallyComprises Perquisites (Total: $189,811 : Company aircraft $56,692, car & driver $6,155, financial planning $15,000, other $111,964), Retirement Contributions (401(k): $33,000 and SRP: $457,645 ), and Other Expenses (HSR Act Fee: $100,000, Charitable Contributions: $10,000; Executive physicals not specified)

    Performance Compensation

    Data from  FY 2023

    Performance Units (Plan-Based Awards)

    Metric/DetailValue/Details
    Performance Metrics & WeightsEPS (50%) and ROIC (50%)
    TSR Modifier±30% adjustment based on TSR ranking relative to S&P 500: +30% if at/above 75th percentile; -30% if at/below 25th percentile; 0% at 50th percentile; linear interpolation in between
    Payout Range30% to 200% of target payout (operating measures range from 30% to 170% + TSR modifier)
    Vesting ScheduleVests at the end of the three-year performance period – December 31, 2025
    Evaluation PeriodJanuary 1, 2023 to December 31, 2025
    Grant DateMay 2, 2023
    Grant Date Fair ValueTotal fair value of $7,956,212; per unit fair value $252.49
    Grant Date Stock Price$235.97 per share
    Additional DetailsDividend equivalents accrue and are payable in shares if the performance units are earned; awards align executive incentives with company performance

    Non-Equity Incentive Plan Awards (EIP/GMIP)

    Metric/DetailValue/Details
    Performance Metrics & WeightsFinancial and operating goals: Deliver Results (60%) – split as Revenue (30%) and Non-GAAP Net Income (30%); Innovative Pipeline (30%); Annual Priorities (10%)
    Composite Score (2023)159.3%
    Target Payout$2,676,669
    Maximum Payout$6,022,505
    Actual Payout (2023)$4,264,000 based on the composite score
    Grant DateMarch 6, 2023
    Grant Date Fair Value$7,956,212 for performance units and $3,182,291 for RSUs
    Grant Date Stock Price$235.97 per share
    Additional DetailsNo explicit thresholds; payout is determined by achieving pre-established operating and financial targets

    These details for 2023 summarize the performance compensation components awarded to Robert A. Bradway. The performance units and non-equity incentive awards are structured to align executive rewards with company financial and operational performance, incorporating strict vesting schedules, precise evaluation periods, and adjustments based on market performance (TSR modifier).